Levagen + Coated Palmitoylethanolamide (PEA)

Hazard statements (CLP)

H315, H318, H361d, H373

Code

Statements

H315

Causes skin irritation

SECTION 2: Hazards identification

Regulation, UK SI 2019/720, and UK SI 2020/1567 Classification of the substance or mixture Classified according to GB-CLP Regulation, UK SI 2019/720 and UK SI 2020/1567 [1] Legend H315 - Skin Corrosion/Irritation Category 2, H318 - Serious Eye Damage/Eye Irritation Category 1, H361d - Reproductive Toxicity Category 2, H373 - Specific Target Organ Toxicity - Repeated Exposure Category 2 Classified by Chemwatch; 2. Classification drawn from GB-CLP Regulation, UK SI 2019/720 and UK SI 2020/1567

Signal word

Danger

Hazard statements

H315 Causes skin irritation. H318 Causes serious eye damage. H361d Suspected of damaging the unborn child. H373 May cause damage to organs through prolonged or repeated exposure. (Oral)

Supplemental label elements

Not Applicable

Prevention

P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust/fume. P280 Wear protective gloves/protective clothing/eye protection/face protection. P264 Wash all exposed external body areas thoroughly after handling.

Response

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P308+P313 IF exposed or concerned: Get medical advice/ attention. P310 Immediately call a POISON CENTER/doctor/physician/first aider. P302+P352 IF ON SKIN: Wash with plenty of soap and water. P332+P313 If skin irritation occurs: Get medical advice/attention. P362+P364 Take off contaminated clothing and wash it before reuse.

Storage

P405 Store locked up.

Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation. Material contains palmitoylethanolamide.

Other hazards

Inhalation and/or ingestion may produce health damage*. Cumulative effects may result following exposure*. May possibly affect fertility*. May possibly be harmful to the foetus/ embryo*. *LIMITED EVIDENCE palmitoylethanolamide Determined to have endocrine-disrupting properties according to Europe Regulation (EU) 528/2012, Europe Regulation (EU) 2017/2100, and Europe Regulation (EU) 2018/605. This substance/mixture does not meet the criteria for classification as Persistent, Bioaccumulative, and Toxic (PBT) in accordance with Annex XIII, Commission Delegated Regulation (EU) 2017/2100, and Commission Regulation (EU) 2018/605. This substance/mixture does not meet the criteria for classification as very Persistent and very Bioaccumulative (vPvB) in accordance with Annex XIII, Commission Delegated Regulation (EU) 2017/2100, and Commission Regulation (EU) 2018/605. This substance/mixture does not meet the criteria for classification as Persistent, Mobile and Toxic (PMT) in accordance with Commission Delegated Regulation (EU) 2023/707. This substance/mixture does not meet the criteria for classification as very Persistent and very Mobile (vPvM) in accordance with Commission Delegated Regulation (EU) 2023/707. No further product hazard information.

2.1 Classification of the substance or mixture

Classified according to GB-CLP Regulation, UK SI H315 - Skin Corrosion/Irritation Category 2, H318 - Serious Eye Damage/Eye Irritation Category 1, H361d - Reproductive 2019/720 and UK SI Toxicity Category 2, H373 - Specific Target Organ Toxicity - Repeated Exposure Category 2 2020/1567 [1] Legend: 1. Classified by Chemwatch; 2. Classification drawn from GB-CLP Regulation, UK SI 2019/720 and UK SI 2020/1567